Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
252
datasets available to search
ShareScore release 0.9.0
Dataset results
252 results for “Myasthenia”
dATASET RELATED TO ARTICLE "Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy"
<p><strong>raw data derived by quantification of complement components and activation products in plasma samples of myasthenia gravis (MG) patients positive for anti-achr and anti-musk autoantibodies and healthy controls, using multiplex immunoassays and elisa</strong></p>
Data from: Serum metabolomics predicts treatment response in myasthenia gravis
<p>High-dose prednisone is the primary initial therapy for myasthenia gravis (MG) but upwards of a third of patients do not respond to treatment. No biomarkers can predict clinical responsiveness to corticosteroid treatment. We conducted a discovery-based study to identify treatment responsive biomarkers in MG using sera obtained at study entry to the thymectomy clinical trial (MGTX), an NIH-sponsored randomized, controlled study of thymectomy plus prednisone versus prednisone alone. We applied ultra-performance liquid chromatography coupled with electro-spray quadrupole time of flight mass spectrometry to obtain comparative serum metabolomic and lipidomic profiles at study entry to correlate with treatment response at 6 months. Treatment response was assessed using validated outcome measures of minimal manifestation status (MMS), MG-Activities of Daily Living (MG-ADL), Quantitative MG (QMG) score, or a strictly defined composite measure of response. Increased levels of phospholipids were associated with treatment response as assessed by QMG, MMS, and the Responders classification, but all measures showed limited overlap in metabolomic profiles, in particular the MG-ADL. A panel including histidine, free fatty acid (13:0), <span>γ-</span>cholestenol and guanosine was highly predictive of the strictly defined treatment response measure. The AUC in Responders' prediction for these markers was 0.90. Pathway analysis suggests that xenobiotic metabolism could play a major role in treatment resistance. We have defined a metabolomic and lipidomic profile that can now undergo validation as treatment predictive markers for MG patients undergoing corticosteroid therapy. Distinct metabolomic profiles were appreciated for each outcome measure.</p>
ASV tables of Myasthenia gravis (MG) and non-Myasthenia gravis
<p><span>Myasthenia gravis (MG) is a neuromuscular junction disease with a complex pathophysiology and clinical variation for which no clear biomarker has been discovered. We hypothesized that because changes in gut microbiome composition often occur in autoimmune diseases, the gut microbiome structures of patients with MG would differ from those without, and supervised machine learning (ML) analysis strategy could be trained using data from gut microbiota for diagnostic screening of MG. Genomic DNA from the stool samples of MG and those without were collected and used to establishe a sequencing library by constructing amplicon sequence variants (ASVs) and completing taxonomic classification of each representative DNA sequence. Four ML methods with nested leave-one-out cross-validation were trained using ASV taxon–based data and full ASV–based data to identify key ASVs in each data set. Overlapping key features extracted when XGBoost was trained using the full ASV–based and ASV taxon–based data were identified, and 31 high-importance ASVs (HIASVs) were obtained. The most significant difference observed was in the abundance of bacteria in the Lachnospiraceae and Ruminococcaceae families. The 31 HIASVs were used to train the XGBoost algorithm to differentiate individuals with and without MG. The model had high diagnostic classification power and could accurately predict and identify patients with MG. In addition, the abundance of Lachnospiraceae was associated with limb weakness severity. </span></p>
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT00727194. IPD Sharing: Not stated. Countries: 3. Publications: 1.
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT04650854. IPD Sharing: YES. Countries: 14. Publications: 2.
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
ClinicalTrials.gov study NCT05681715. IPD Sharing: YES. Countries: 10. Publications: 1.
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT05070858. IPD Sharing: YES. Countries: 19. Publications: 0.
The Evaluation of Belimumab in Myasthenia Gravis (MG)
ClinicalTrials.gov study NCT01480596. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Disease-Modifying Treatments for Myasthenia Gravis
ClinicalTrials.gov study NCT03490539. IPD Sharing: NO. Countries: 2. Publications: 14.
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT03920293. IPD Sharing: Not stated. Countries: 15. Publications: 4.
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
ClinicalTrials.gov study NCT03770403. IPD Sharing: NO. Countries: 15. Publications: 2.
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complemen
ClinicalTrials.gov study NCT05514873. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT04115293. IPD Sharing: YES. Countries: 10. Publications: 4.
Myasthenia Gravis Inebilizumab Trial
ClinicalTrials.gov study NCT04524273. IPD Sharing: Not stated. Countries: 19. Publications: 1.
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT03971422. IPD Sharing: YES. Countries: 17. Publications: 7.
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT02473952. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT03315130. IPD Sharing: NO. Countries: 2. Publications: 1.
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
ClinicalTrials.gov study NCT02950155. IPD Sharing: NO. Countries: 1. Publications: 1.
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
ClinicalTrials.gov study NCT03669588. IPD Sharing: NO. Countries: 16. Publications: 3.
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT06371040. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.